Limitations of Conventional Contrast-enhanced MRI in Selecting Sentinel Node Biopsy Candidates among DCIS Patients by Moon, Hyeong-Gon et al.
INTRODUCTION
Although recent understanding of tumor biology has
lead to improved management of ductal carcinoma in situ
(DCIS), there are still certain areas that are controversial.(1)
Among them lies the issue of performing sentinel node
biopsy in patients with a preoperative diagnosis of DCIS.(2)
The underlying rationale for performing sentinel node
biopsy in DCIS patients is the possible upstaging to inva-
sive cancer, which happens in up to 50% of needle biopsy
cases,(3,4) a misfortune that almost always leads to addi-
tional surgical procedures for axillary staging if a sentinel
node biopsy has not been performed at the time of initial
surgery. A recent meta-analysis suggested that the inci-
dence of a positive sentinel node in the preoperative diag-
nosis of DCIS is 7.4% based on 22 published studies, and
concluded in favor of the routine use of the procedure.(5)
However, current guidelines on DCIS management
recommend against the routine use of sentinel node biop-
sy, especially if the patient is suitable for breast conser-
vation.(6,7) These guidelines are mainly the result of
consensus among those who acknowledge both the low
yield rate of a positive sentinel node in patients with local-
ized DCIS and the potential long-term sequelae that may
accompany the procedure.(8,9) Despite these recommen-
dations, a recent review of the Surveillance, Epidemiology
and End Results (SEER) data from 1998 to 2002 revealed
that 22.5% of DCIS patients undergoing breast conser-
vation had received axillary lymph node assessment,
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and 67% of the assessments were axillary dissections.(10)
These apparent discrepancies between recommendations
and clinical practice reflect the lack of a validated model
to predict a subset of patients with high risk of invasive
cancer, which would enable more tailored patient selection. 
Recent researches involving the use of magnetic res-
onance imaging (MRI) in DCIS patients had shown an
increased detection rate and more accurate estimation
of tumor extent with MRI when compared to conven-
tional mammography.(3,11-14) Furthermore, studies
have suggested that the pharmacokinetics of contrast-
enhanced MRI (patterns of enhancement and washout)
may provide more detailed information regarding the
presence of occult invasion in DCIS patients.(15,16) Other
imaging modalities, such as ultrasonography, have shown
limitations in predicting invasive disease.(4) In this study,
we hypothesized that morphologic and pharmacokinetic
features of contrast-enhanced MRI may predict the pres-
ence of occult invasion in patients with preoperative
diagnosis of DCIS, and will thereby guide the selective
use of sentinel node biopsy in these patients. 
METHODS
Patients and MRI protocol
This was a retrospective study based on a prospectively
maintained database. The database includes clinico-
pathologic and follow-up data of all patients who under-
went breast surgery at the Seoul National University
Hospital. Patients with a preoperative diagnosis of DCIS
who underwent surgery in the Seoul National University
Hospital between January 2007 and July 2008 were iden-
tified from a prospectively maintained database in the
Seoul National University Hospital Breast Care Center.(17)
During the study period, a total of 180 consecutive patients
with a preoperative diagnosis of DCIS underwent curative
surgery. Among them, 11 patients who received prior
surgical excision of the suspicious lesion were excluded
from analysis leaving 169 patients diagnosed by 11-gauge
vacuum assisted or 14 gauge automated needle biopsies.
Preoperative contrast-enhanced MRIs were not done in
26 patients for various reasons (e.g., patients’refusal,
renal dysfunction). The remaining 143 patients were
included in the analysis. Each patient underwent contrast-
enhanced MRI before surgery to determine the extent of
the tumor and the presence of occult multifocal lesions.
Our protocols for MRI image acquisition and pathologic
examination of breast cancer patients have been previ-
ously described.(17)Briefly, MRI was carried out with a 1.5-
T imager (Sonata; Siemens Medical Systems, Erlangen,
Germany or Signa; General Electric Medical Systems,
Milwaukee, USA) using a dedicated breast coil (Liberty
5000; USA Instruments, Aurora, USA). A bolus of gado-
pentetate dimeglumine (Magnevist; Schering, Berlin,
Germany) was injected i.v. at a dose of 0.1 mmol/kg of
body weight within 15 s, followed by a 20 mL saline solu-
tion flush. MRI images were reviewed by a specialized
radiologist who was blinded to the pathologic information
of the studied patients. Morphologic and kinetic features
of MRI images were described according to the BIRADS
(Breast Imaging Reporting and Data System) MRI lexi-
con.(18)
SD=standard deviation; USG=ultrasonography; MRI=magnetic reso-





Non-palpable lesion 81 (56.6)
Palpable lesion 62 (43.4)
USG size (cm) 2.5±1.6
MRI size (cm) 3.5±2.0
Diagnostic procedure
14-gauge needle biopsy 79 (55.2)




Pathologic DCIS size (cm) 3.5±2.0





Positive axillary LN 6 (4.2)
Negative axillary LN 137 (95.8)
Table 1. Clinicopathologic information of studied patients
Clinicopathologic parameters Mean±SD No. (%)
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Diagnostic procedures and statistical analysis 
Needle biopsies were performed with an 11-gauge vac-
uum-assisted device (Mammotome; Ethicon-Endosurgery,
Cincinnati, USA) or a 14-gauge automated gun (Pro-Mag
2.2; Manan Medical Products, Northbrook, USA) under
sonographic guidance with 10- or 12-MHz linear trans-
ducers (Kretz-Medicon; Seoul, Korea; HDI 5000; Advanced
Technology Laboratories, Bothel, USA). For lesions not
visible on ultrasonography, a wire was localized under
mammographic guidance and 11-gauge vacuum-assisted
biopsies were done under sonographic monitoring of the
inserted wires. Each biopsy specimen was stained with
hematoxylin and eosin and examined by a specialized
breast pathologist. 
Statistical analysis was done using a two-tailed chi-
square test and Student’s t-test to compare differences
in nominal and continuous variables between groups,
respectively. The SPSS for Windows statistical software
package (SPSS Inc., Chicago, USA) was used to do the
analyses. A p value of <0.05 was considered statistically
significant.
RESULTS
Demographic and pathologic information of the studied
patients are shown in Table 1. Preoperative diagnoses
were made by 11-gauge vacuum assisted biopsy in 64
patients (44.8%) and by 14-gaude needle biopsy in 79
Table 2. Association between various clinicopathologic factors and the presence of occult invasion
Clinicopathologic features
Final pathology
OR (95% CI) p-value
DCIS, No. (%) IDC, No. (%)
Mean age±SD (yr) 48.2±10.3 48.5±8.0 0.850
Mean MRI size±SD (cm) 3.27±1.92 3.79±2.06 0.121
Mean USG size±SD (cm) 2.18±1.59 2.77±1.60 0.046
Palpation 4.64 (2.28-9.43) <0.001
Non-palpable lesion 57 (70.4) 24 (29.6)
Palpable lesion 21 (33.9) 41 (66.1)
Type of biopsy 2.57 (1.29-5.11) 0.006
11-gauge needle biopsy 43 (67.2) 21 (32.8)
14-gauge needle biopsy 35 (44.3) 44 (55.7)
Suspicious areas of microinvasion 3.59 (1.38-9.32) 0.006
Absent 71 (59.7) 48 (40.3)
Present 7 (29.2) 17 (70.8)
Histologic grade* 1.61 (0.79-3.26) 0.185
Low (Grade 1-2) 33 (62.3) 20 (37.7)
High (Grade 3) 41 (50.6) 40 (49.4)
Mass on USG 1.78 (0.63-5.06) 0.269
No mass appearance 12 (66.7) 6 (33.3)
Mass appearance 66 (52.8) 59 (47.2)
USG lesion size�(cm) 2.11 (1.03-4.34) 0.041
<2 40 (61.5) 25 (38.5)
≥2 25 (43.1) 33 (56.9)
Comedonecrosis� 1.04 (0.54-2.03) 0.903
Absent 40 (54.1) 34 (45.9)
Present 35 (53.0) 31 (47.0)
Mass on MMG 2.18 (1.00-4.75) 0.047
Absent 64 (59.3) 44 (40.7)
Present 14 (40.0) 21 (60.0)
DCIS=ductal carcinoma in situ ; IDC=invasive ductal carcinoma; OR=odds ratio; CI=confidence interval; SD=standard deviation; MRI=magnetic
resonance imaging; USG=ultrasonography; MMG=mammography.
*Pathologic information regarding histologic grades was not available for 10 patients; �Ultrasonographic lesion size was unmeasurable in 20 patients;
�Pathologic information regarding the presence of comedonecrosis was not available in 3 patients. 
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patients (55.2%). Among the 143 patients in whom the
preoperative diagnoses were DCIS, 65 patients (45.5%)
were upstaged to invasive carcinoma after curative resec-
tion. Contrast-enhanced MRI predicted tumor size more
accurately than ultrasonography did (Pearson’s correlation
coefficients of 0.665 and 0.556, respectively). 
The association of occult invasion and various clinico-
pathologic parameters was examined and is shown in
Table 2. In accordance with our previous report,(4) the
presence of a physically palpable lesion, a mass on mam-
mography, and the ultrasonographic lesion size were
significantly associated with the presence of invasive
cancer. Additionally, patients who were diagnosed by
14-gauge needle biopsy and in whom initial pathologic
findings showed suspicious microinvasion had a signif-
icantly higher incidence of occult invasive cancer (OR of
2.57 [95% CI, 1.29-5.11] and 3.59 [1.38-9.32], respectively).
A higher histologic grade and the presence of comedo
necrosis did not show a significant relationship with occult
invasion. 
In terms of morphologic parameters of contrast-en-
hanced MRI and their association with occult invasion,
only mass-appearance on MRI was significantly asso-
ciated with the presence of invasive cancer (OR of 3.56
[95% CI, 1.58-8.04], p=0.002). However, among the 35
patients who had mass-appearance in MRI, 17 patients
(48.6%) had mass-appearance in mammography as well.
Other morphologic parameters, such as margin, shape,
and enhancement pattern, did not have a significant
association with the presence of invasive cancer (Table
3). Furthermore, MRI pharmacokinetic characteristics
of the tumor (initial enhancement and washout pattern)
did not predict occult invasive cancer (Table 3). Subgroup
analysis according to the size of needle (14 gauge vs. 11
gauge) also showed a lack of significant association bet-
ween certain MRI characteristics and the presence of
invasive cancer.
DISCUSSION
Our hypothesis that contrast-enhanced MRI charac-
teristics may predict the presence of occult invasion in
patients with a preoperative diagnosis of DCIS was mainly
based upon two aspects. The first was the recent interest




OR (95% CI) p-value
DCIS, No. (%) IDC, No. (%)
Mass 3.56 (1.58-8.04) 0.002
Non-mass-like enhancement 67 (62.0) 41 (38.0)
Mass-appearance 11 (31.4) 24 (68.6)
Shape 0.84 (0.14-5.22) 0.619
Round or oval 2 (28.6) 5 (71.4)
Irregular 9 (32.1) 19 (67.9)
Margin 2.44 (0.29-20.12) 0.575
Round or clear 2 (50.0) 2 (50.0)
Irregular or spiculated 9 (29.0) 22 (71.0)
Enhancement 1.87 (0.34-10.3) 0.652
Homogeneous or dark-septated 3 (42.9) 4 (57.1)
Heterogeneous or rim-enhancement 8 (28.6) 20 (71.4)
Pharmacokinetics (enhancement)* 1.13 (0.53-2.39) 0.749
Medium or slow 22 (53.7) 19 (46.3)
Rapid 42 (50.6) 41 (49.4)
Pharmacokinetics (washout)* 1.44 (0.61-3.40) 0.399
Plateau or persistant 52 (53.6) 45 (46.4)
Rapid 12 (44.4) 15 (55.6)
DCIS=ductal carcinoma in situ ; IDC=invasive ductal carcinoma; OR=odds ratio; CI=confidence interval; MRI=magnetic resonance imaging.
*Pathologic information regarding histologic grades was not available for 10 patients. 
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in the use of MRI in breast cancer patients.(14) Contrast-
enhanced MRI provides more detailed and accurate infor-
mation in certain breast cancer patients when compared
to conventional mammography and ultrasonography.
although its role in DCIS in still controversial.(19) The
other motivation came from the underlying mechanism
of contrast-enhanced MRI in delineating malignant breast
tumors, which is the leak of contrast agent into the highly
vascularized tissues located in and around the breast
cancer cell nests. Recent studies have shown that mole-
cular changes in stromal tissue of pure in situ breast
tumors play a critical role in tumor invasion and pro-
gression.(20) Furthermore, vascular stroma formation
or neo-vascularization may precede the invasion of in
situ tumors.(21,22) Based on these recent observations,
we postulated that stromal changes in DCIS patients may
enable the contrast-enhanced MRI to select high risk
patient group of invasive disease.
However, in our study, we could not identify contrast-
enhanced MRI characteristics that predict the presence
of occult invasion except for mass appearance on MRI.
Previous studies have shown that DCIS patients with a
clinically palpable breast mass or a radiographic breast
nodule have increased risk of having occult invasive dis-
ease.(4,23-25) Our finding of an association between mass
appearance on MRI and occult invasive cancer is in con-
cordance with these previous reports. However, even
among patients with mass appearance on MRI, about 30%
had no evidence of invasive carcinoma and up to 50% also
showed mass-appearance in mammography, reflecting
the limitation of conventional contrast-enhanced breast
MRI and the need for a more accurate prediction model.
Hwang et al.(16) in their study of 51 DCIS patients
showed improved sensitivity and negative predictive
value in predicting occult invasion in DCIS patients by
using contrast-enhanced MRI. Additionally, from their
analysis of 15 DCIS patients Groves et al.(15) reported
the association of certain enhancement patterns and MRI
shapes with pure DCIS. Certain morphologic and phar-
macokinetic features of contrast-enhanced MRI such as
a spiculated margin and a rapid washout pattern have
often been suggested as predictive features of invasive
disease.(16) However, in our study, mass shape, margin,
enhancement pattern, and pharmacokinetic features of
contrast-enhanced MRI did not have significant predictive
value. Similarly, Facius et al.(26) showed, in their study
of 74 patients, that 68% of pure DCIS had MRI features
of invasive breast cancer. 
Although we could not demonstrate highly accurate
MRI features that predict occult invasion in DCIS patients,
we believe that our results should not discourage the
efforts of others in developing novel imaging biomarkers
in DCIS patients. For example, recent advances in dif-
fusion-weighted MRI and other molecular imaging could
lead to a more tailored approach in DCIS patients.(1)
Meanwhile, however, efforts should be made to improve
and develop a novel MRI lexicon that may predict occult
invasion and thereby guide the use of sentinel node biopsy
in DCIS patients. Another important direction in devel-
oping a valid predictive model to provide a more tailored
use of sentinel node biopsy in DCIS patients would be
the molecular approach. Recent research advances have
given novel insights into the progression and invasion
process of DCIS in terms of molecular expression profiles
and stromal phenotypes.(20,27-30) Potential molecular
markers from recent studies should be validated in a
prospective setting to determine their possible role as
molecular markers for selecting DCIS candidates for sen-
tinel node biopsy.
CONCLUSION
In this study of 143 consecutive patients, we tried to
demonstrate the clinical usefulness of contrast-enhanced
MRI in predicting invasive disease for patients with pre-
operative diagnoses of DCIS. Among the features of MRI,
only mass-appearance was significantly associated with
the presence of invasive disease. However, about 50%
instances of mass on MRI cases had mass-appearance on
mammography as well. Other morphologic and pharma-
cokinetic features of MRI, such as shape, margin, and
patterns of enhancement and washout, did not have a
significant association. Our results show the limitations
of current contrast-enhanced MRI in predicting invasive
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disease in patients with preoperative diagnoses of DCIS.
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